Primary biliary cirrhosis (PBC) is an autoimmune disease characterized by intrahepatic bile duct destruction and the production of anti-mitochondrial antibodies (AMA). The absence of an animal model has been a striking impedance in defining the molecular basis of disease. Previous work has suggested that SJL/J mice immunize with the pyruvate dehydrogenase complex (PDC-E2), the major mitochondrial autoantigen of PBC, leads to the development of lymphoid cell infiltration in portal tracts and a model system coined autoimmune cholangitis. We hypothesized that this pathology would be augmented if immunization occurred in the presence of IFN-g injections. Accordingly, SJL/J mice were immunized with PDC-E2 and, for purpose of control, a-casein. Subgroups of mice were also treated with exogenous IFN-g. As expected, mice immunized with PDC-E2, with or without IFN-g, developed high titer AMAs. In contrast, mice immunized with a-casein, develop antinuclear antibodies. More importantly, the livers from mice immunized with PDC-E2 and/or those immunized with a-casein all displayed lymphoid cell infiltration to the portal tracts, irrespective of bile duct size. Indeed, there was no significant difference between the experimental and the control groups by histologic analysis. Thus, autoimmune cholangitis in these mice is antigen non-specific.
INTRODUCTION
Primary biliary cirrhosis (PBC) is a chronic inflammatory, organ specific autoimmune disease of the liver characterized by high titer anti-mitochondrial antibodies (AMA) and intrahepatic bile duct destruction (Nakanuma and Ohta, 1979; Scheuer, 1994; Kaplan, 1996) . The etiology and pathogenesis of PBC are unknown. High titer AMA react with a series of highly conserved intramitochondrial proteins including the E2 subunit of the pyruvate dehydrogenase complex (PDC-E2), the major autoantigen of PBC. Whether liver injury is caused by AMA (Malmborg et al., 1998; Feehally and Allen, 1999) , PDC-E2 specific T cells (Van de Water et al., 1997; Shimoda et al., 1998; Inada et al., 2000) , NK cells (Tsuneyama et al., 1998; Iwata et al., 2000) or pathological alterations of the bile ducts themselves (Yasoshima et al., 1995; Kimura et al., 1996; Leon et al., 1997) are all being investigated. However, it is important to bear in mind that PBC is an autoimmune disease that most likely develops as a multi-hit disease, not just one insult. It has been theorized that PBC, in a genetically susceptible host, may be initiated by a molecular mimic (Coppel and Gershwin, 1995; Shimoda et al., 2000) or a xenobiotic (Uibo and Salupere, 1999; Long et al., 2001) . However, to this end, no definitive causative agent has, as yet, been identified.
The first reported animal model for PBC was observed in an inbred rabbit strain with spontaneous nonsuppurative cholangitis (Tison et al., 1982) . However, the specificity and repertoire of AMA in these rabbits failed to mimic human disease. More recently, PBC epithelial cells were injected intravenously into neonatally thymectomized A/J mice on the premise that altered epithelial cells may initiate disease (Kobashi et al., 1994; Masanaga et al., 1998) . Also, injection of C57BL/6 mice with purified PDH in LPS or injection of recombinant polypeptides of PDC-E2 (Ide et al., 1996; Kimura et al., 1996) have been attempted. However, although AMAs were induced in all of these proposed models, pathological changes in the liver similar to human PBC were not induced. In contrast, a GVHD model for PBC has also been developed which induces histological pathology but serological responses are not specific for mitochondrial antigens (Tanaka et al., 1999; Zeniya, 2000) . As a whole, all animal models developed to date fail to accurately mimic human PBC by the induction of both AMA and intrahepatic liver damage. With these observations in mind, Jones et al. (2000) reported the appearance of autoimmune cholangitis in SJL/J mice following the immunization of bovine PDC-E2, emulsified in CFA. The SJL/J mouse was chosen because it has been successfully used as models of other autoimmune disease, including experimental allergic encephalomyelitis, systemic lupus erythematosus and mercury induced immunopathology (Vidal et al., 1994; Abedi-Valugerdi and Moller, 2000; Winer et al., 2001) . Further, T cells isolated from affected mice displayed a mixed Th1/Th2 response when stimulated with autoantigen in vitro (Jones et al., 1999) . IFN-g is a Th1 cytokine involved in the generation of antigen-specific T cells and has already been shown to be involved in induction of experimental myasthenia gravis (Wang et al., 2000) . Therefore, we hypothesized that injection of exogenous IFN-g would enhance the development of a PBC-like disease in SJL/J mice immunized with bovine PDC-E2. However, we report herein that while SJL/J mice do demonstrate evidence of significant cholangitis, that such cholangitis is antigen non-specific regardless of IFN-g injection and thus not reflective of PBC.
MATERIALS AND METHODS

Antigens
A mitochondrial fraction isolated from bovine heart tissue was prepared as described previously (Fregeau et al., 1990) ; native PDC-E2 was thence purified (Stanley and Perham, 1980) . As a negative control, a-casein, was purchased from Sigma Inc. (St Louis, MO). A lipoated, huPDC-E2 peptide (p163) spanning amino acids 163-176 (GDLLAEIETDKATI), previously shown to be a major T cell epitope (6 -8), was synthesized by Alpha Diagnostic International (San Antonio, TX). Peptide purity was confirmed by reversed phase HPLC.
Immunization
Female SJL/J mice were obtained from Jackson Laboratories (Bar Harbor, ME) and all procedures conducted according to the principles outlined in the Guidelines of the Committee on Care and Use of Laboratory Animals. In the first set of experiments, mice were immunized at 12 weeks of age with a single 200 ml intraperitoneal injection of 500 mg of either bovine PDC-E2 or a-casein emulsified in complete Freund's adjuvant as described (Jones et al., 2000) ; the complete Freund's adjuvant (CFA) used contained 10 mg/ml Mycobacterium tuberculosis strain H37Ra (Difco) in incomplete Freund's adjuvant purchased from Sigma Inc. (St Louis, MO). In subgroups of mice, 3000 units of murine recombinant IFN-g was administered intraperitoneally twice a week for four weeks (Kyuwa et al., 1998) . The mice were divided into the following groups: (A) PDC-E2; (B) PDC-E2 and IFNg; (C) a-casein; and (D) a-casein and IFN-g in groups of 8 -12 animals (Table I ). Mice were serially observed and by 30 weeks of age, mice were sacrificed. This time period was chosen based on earlier observations by Jones et al. (2000) . Sera were assayed for autoantibodies. In addition, the liver, salivary gland, thymus, lung, heart, kidney, spleen, stomach, small and large intestine, were all removed for evaluation. Tissue specimens were fixed with 10% neutral buffered formalin and embedded in paraffin. Deparaffinized thin sections from each paraffin block were stained with hematoxylin and eosin for histology. Because some pilot data suggested the possibility of amyloid deposition, a Direct Fast Scarlet stain was performed and tissues viewed using polarized microscopy.
In the second set of experiments, two groups of five mice were immunized at 8 weeks of age with a single 200 ul intraperitoneal injection of the following: (E) 50 ug of p163 in incomplete Freund's adjuvant (IFA); or (F) IFA alone. Mice were serially observed and at 36 weeks of age, they were sacrificed. Sera were assayed for autoantibodies. The livers were removed for evaluation as described above.
Autoantibodies
Antimitochondrial antibodies were assayed using a combination of ELISA, immunoblotting and immunohistochemical staining of HEp-2 cells. For ELISA, microtiter plates were coated with 10 mg/ml PDC-E2 suspended in carbonate buffer (pH 9.6) and incubated overnight at 48C. After washing three times with 0.05% Tween-20 in PBS (PBS/Tween), plates were blocked with 3% milk in PBS for 1 h at room temperature (RT). Diluted mouse sera (1:200) was distributed into individual wells and incubated for 1 h at RT. After washing, the plates were incubated with 0.1 ml of HRP-conjugated goat anti-mouse immunoglobulin (Zymed, South San Francisco, CA) for 1 h. Reactivity was visualized by addition of 40 mM 2,2 0 -azinobis (3-ethylbenzthiazoline-6-sulfonic acid) dissolved in 0.05 M citric acid buffer (pH 5) containing 0.5 M H 2 O 2 . The reaction was stopped after 15 min by the addition of 5% SDS. Reactivity was measured using a Wallac spectrophotometer at a wavelength of 405 nm. Known positive and negative sera were included with each assay. For immunoblotting, samples were suspended in 250 ml of sample buffer (125 M Tris -HCl (pH6.8) containing 4% SDS, 20% glycerol and 5% 2-ME), boiled for 5 min, and resolved by SDS-PAGE using 1.5 mm-thick slab gels with a 4.75% stacking gel and a 10% separating gel. Separated proteins were transferred electrophoretically to nitrocellulose filters purchased from Micron Separations (Westboro, MA). After transfer, nitrocellulose filters were cut into strips, blocked with 3% milk in PBS for 1 h at RT and probed by incubation for 1 h with mouse sera diluted at 1:200. After washing with PBS/Tween, strips were incubated for an additional hour with HRP-labeled goat anti-mouse or anti-human polyvalent immunoglobulin (1: 2000). Strips were washed and visualized with enhanced chemiluminescent substrate purchased from Pierce (Rockford, IL). Known AMA positive PBC sera and control negative sera were used throughout these studies as controls.
Immunohistochemical staining of Hep-2 cells were performed using Hep-2 cell slides purchased from Antibodies Inc. (Davis, CA). Slides were incubated at RT for 1 h with SJL/J mice sera, human PBC sera or control sera diluted at 1:40. After incubation, slides were washed in PBS for 10 min. The reaction was followed by a 30 min incubation with FITC-conjugated goat anti-mouse or anti-human IgG diluted in PBS. Once again, known positive and negative sera were used throughout.
RESULTS
Induction of Antimitochondrial Antibodies
One defining serologic characteristic of PBC is the development of high titer AMA specific for the E2 subunit of PDC-E2 . Mice were bled and screened for the development of AMA. All sera collected at 7 weeks from SJL/J mice immunized with PDC-E2 (group A) showed positive reactivity against PDC-E2 by immunoblot (Fig. 1, lanes 1 and 2) . In contrast, sera isolated at 7 weeks from mice immunized with a-casein (group C) failed to react with PDC-E2 (Fig. 1, lane 3) . All responses from mice immunized with PDC-E2 (group A) were similar to responses of mice immunized with PDC-E2 plus IFN-g (group B), including reactivity with the conserved inner lipoyl domain of PDC-E2 (data not shown). At subsequent time points, through sacrifice (30 weeks), sera reactivity was very much similar to that determined at 7 weeks post-immunization (Fig. 1, lanes 4  and 5) . In contrast, sera isolated at 30 weeks from mice immunized with a-casein (group C) failed to react with PDC-E2 (Fig. 1, lane 6) . Results performed by immunoblot were similar to those obtained by ELISA. Further, sera from mice primed with PDC-E2 (Groups A and B) displayed a typical speckled (punctate) antimitochondrial staining pattern (Fig. 2a) . However, a single mouse primed with PDC-E2 and who received IFN-g (group B) demonstrated an anti-nuclear antibody pattern at a 1:40 dilution. Sera isolated from mice immunized with a-casein (groups C and D) also displayed weak antinuclear antibody staining patterns (Fig. 2b) .
Chronic Inflammation in Hepatic Bile Ducts
At 7 and 30 weeks post-immunization, chronic portal inflammation and granulomas were observed in all mice, irrespective of the antigen used (Table I, Fig. 3a and b) . Mild bile duct injuries were prevalent as demonstrated by the irregular arrangement of the biliary epithelium (Fig. 3c) . Moreover, significant lymphoid cell infiltration into the biliary epithelium and isolated apoptotic biliary FIGURE 1 Immunization of SJL/J mice with PDC-E2 induces AMA. Sera isolated from SJL/J mice immunized with PDC-E2 as well as PBC patient sera recognized PDC-E2 (74 kD) and OGDC (48 kD). Lanes 1 and 2 represent sera isolated at 7 weeks from mice immunized with PDC-E2. Lane 3 represents sera isolated at 7 weeks from a mouse immunized with a-casein. Lanes 4 and 5 represent sera isolated at 30 weeks from mice immunized with PDC-E2. Lane 6 represents sera isolated at 30 weeks from mice immunized with a-casein. Lane 7 is serum from a PBC patient.
epithelial cells were observed in all groups. Of note, this pathology was observed in both small and large bile ducts (data not shown). Loss of bile ducts and destruction of the portal tracts leading to cirrhosis failed to develop in any mice.
Interestingly, focally globular amyloid depositions developed along the walls of hepatic vessels in mice immunized with bovine PDC-E2 regardless of IFN-g treatment (Fig. 3d) . These amyloid depositions were characterized as AA type as the amyloid was sensitive to KMnO 4 treatment. In contrast, amyloid deposition was not detected in mice injected with the a-casein and there was no significant difference in histology between a-casein groups treated with or without IFN-g administration (data not shown).
Selected Organs Lack Indications of Injury Due to Chronic Inflammation
Although PDC-E2 is a ubiquitous antigen found in every cell in the body, pathology is localized to small bile ducts and salivary glands. Thus, it was important to confirm the specificity of the immune response induced by injection of bovine PDC-E2 by not only analyzing liver tissue, but also selected control tissues. It was interesting that there was lymphoid cell infiltration associated with mild duct injuries in the salivary glands of mice in all groups (Fig. 3e) . Moreover, after 30 weeks, lymph node swelling was evident in all mice. However, in contrast to the liver and salivary glands, there were no indications of significant inflammatory responses in other organs. Thus, immune responses to bovine PDC-E2 and a-casein with or without IFN-g were localized to the ducts of the liver and salivary glands and appeared to be due to CFA or impurities in our antigen preparations.
Immunization with Incomplete Freund's Adjuvant is Sufficient to Induce Portal Inflammation with Bile Duct Invasion and Damage
The initial study by Jones et al. (23) indicated that immunization of SJL/J mice with an immunogenic huPDC-E2 peptide (p163) was as effective as whole, bovine PDC in inducing hepatic histologic changes characteristic of PBC. To eliminate differences in antigen and CFA preparation as a reason for the difference between our results and those of Jones et al., studies were conducted using synthesized p163 and IFA. At 36 weeks post-immunization, we observed significant chronic portal inflammation with bile duct invasion and damage in 2 of 5 mice injected with lipoated p163 þ IFA (Table II) . No granulomas were detected in any of these livers. Low titers of anti-PDC-E2 antibodies were detected by immunoblotting against purified human PDC-E2 only in the sera of the two mice with histologic changes (data not shown). Pre-incubation of sera with p163 inhibited immunoblotting of huPDC-E2. However, portal inflammation with bile duct invasion and damage, though less severe, was also observed in 3 of 5 mice injected with IFA alone. Granulomas were observed in two of these mice. Anti-PDC-E2 antibodies were not detected in the sera of these mice. Serum alkaline phosphatase levels were elevated only in the mouse (E4) with the most severe portal tract damage (data not shown). Portal inflammation with bile duct damage occurred as frequently in SJL/J mice injected with IFA alone as compared to mice injected with p163 and IFA. 
DISCUSSION
PBC is an autoimmune disease associated with an inflammatory response localized to the small bile duct cells of the liver Ludwig, 2000) . While attempts to establish an animal model for PBC in a number of animal species, including several strains of mice, have had with little success (Krams et al., 1989; Zeniya, 2000) , Jones et al. have proposed an animal model for PBC termed "experimental autoimmune cholangitis" in which SJL/J mice are immunized with purified bovine PDC-E2 (Jones et al., 2000) . Both the use of SJL/J mice and bovine PDC-E2 may have been important factors in establishing this proposed model of PBC. Unclear susceptibility factors in SJL/J mice have made these mice useful for the establishment of models of other autoimmune diseases (Vidal et al., 1994; Abedi-Valugerdi and Moller, 2000; Winer et al., 2001) . Additionally, purified bovine PDC-E2 may be more efficient at inducing an immune response for several reasons. In our hands, native PDC-E2 isolated from bovine heart tissue induces a stronger response than E. coli-produced recombinant protein when injected into mice (unpublished data). First, it has been suggested that lipoic acid is essential for optimal antigenicity (Fregeau et al., 1990; Bassendine et al., 1998; Koike et al., 1998) . Native protein is lipoated while synthetic peptides and recombinant proteins may not be lipoated. Second, it is important to note that bovine PDC-E2 differs from murine PDC-E2 by 28% at the amino acid level as determined by a protein blast. However, the antigenic region of bovine PDC-E2, including lipoic acid, has high homology with the murine protein and thus select regions may be recognized as a foreign antigen or altered self by the murine immune system. It thus may induce a stronger immune response against the autoantigen than a recombinant self protein or peptide (Coppel and Gershwin, 1995; Mackay, 2000) .
In the study herein, we conducted a thorough serologic and histologic review to evaluate the premise that the SJL/J mouse is a suitable animal model for PBC. We also injected purified bovine PDC-E2 as the antigen to initiate the immune response in SJL/J mice. Our control group was not injected with CFA alone, as in the study by Jones et al., but with a-Casein and CFA. Mild bile duct pathology was induced by immunization with bovine PDC-E2 emulsified in CFA. However, similar pathology was also noted in the mice immunized with the control protein (a-Casein) emulsified in the same adjuvant. Antigen specific AMA were successfully induced in experimental SJL/J mice but not control mice. However, the characteristic bile duct injury typical of PBC failed to develop even after 30 weeks, although mild bile duct pathology and portal inflammation persisted. Furthermore, inflammation and diffuse bile duct pathology were observed, irrespective of bile duct size. In contrast, only small bile ducts are damaged in human PBC and affected bile ducts are distributed sparsely, not diffusely (Sasaki et al., 2000) .
To magnify the inflammatory environment in SJL/J mice, we injected exogenous IFN-g but such injections failed to alter the pathology of PBC. The addition of IFN-g did not change the specificity or intensity of histologic or serologic effects. These results are not surprising since the pathology observed herein is antigen non-specific. Hence, this system is different from the disease associated features of IFN-g when NOD mice are injected with exogenous cytokines (Xiang and Zaccone, 1999) . Alternatively, treatment of IFN-g may cause classswitching of antigen specific AMA to IgG1. It is possible that IgG1 is not pathogenic. In fact, recently our lab has demonstrated that IgA may significantly contribute to the pathology of PBC (Reynoso-Paz et al., 2000) . In this respect, we should note that mice do not have IgA receptors on their bile duct cells and, in fact, have a significantly different mucosal immune system than that of humans .
To eliminate non-specific effects caused by impurities in our antigen or adjuvant preparations, SJL/J mice were also injected with a lipoated, immunogenic huPDC-E2 peptide (aa 163 -176) emulsified in IFA or with IFA alone. Portal inflammation with bile duct invasion and damage occurred with similar frequency in both groups. There is no indication that the development of portal inflammation was specific to a loss of tolerance to PDC-E2, though the severity of inflammation was greater in mice expressing anti-PDC-E2 autoantibodies. Thus, both the development of autoantibodies and portal tract inflammation may simply reflect the severity of the inflammatory response following ip injection. SJL/J mice appear to be predisposed to the development of portal inflammation with minimal provocation.
It is of interest that systemic amyloidosis of AA type was induced in most of the SJL/J mice immunized with PDC-E2 but not in controls with a-casein. Generally, AA type amyloidosis occurs secondary to systemic chronic inflammatory changes such as rheumatoid arthritis and tuberculosis. Heretofore, AA amyloidosis in mice has been previously induced in a number of strains of mice by repeated injections of a-casein, chemicals and endotoxin (Skinner et al., 1977; Baumal, 1979; Rokita et al., 1989; Kisilevsky and Young, 1994; Sipe, 1994) , and in a transgenic mouse model carrying human IL-6 gene with mouse metallothionein-I promoter (Solomon et al., 1999) . Spontaneous amyloid deposits have also been noted in aged SJL/J mice. In fact, the injection of amyloid enhancing factor (AEF) together with a-casein in CFA induced AA amyloidosis in SJL/J mice, while a-casein alone did not induce amyloidosis (Rokita et al., 1989) . Our findings are in agreement with these findings but not those of Jones et al. (1999) .
The SJL/J mouse is an interesting model for a number of diseases and it remains possible that with further study, significant information may be forthcoming on the inflammatory environment within the liver and salivary glands. However, it appears that such responses are antigen non-specific.
